Retatrutide (LY3437943), a novel peptide agonist of the GLP-1, GIP, and glucagon receptors, represents one of the most significant advances in metabolic research over the past two years. Unlike earlier GLP-1-only agonists or dual GIP/GLP-1 compounds, retatrutide's triple mechanism engages three separate metabolic pathways simultaneously, producing unprecedented weight reduction and hepatic fat clearance in Phase 2 and Phase 3 trials. This article reviews the mechanism, published data, and the implications for obesity and metabolic disease research.
Retatrutide activates three hormone receptors—each with distinct metabolic roles:
The breakthrough: adding glucagon receptor activation to GIP/GLP-1 agonism did not cause problematic hyperglycemia (a long-standing concern) because the insulin secretion from GLP-1/GIP dominates when glucose is high. The glucagon receptor activation instead enhances fat loss in the liver and elsewhere.
Phase 2 trials (2023–2024): Initial studies of retatrutide showed average weight loss of 24.2% after 48 weeks at the highest dose tested. For context, this approaches the weight loss seen after bariatric surgery, and exceeds results from dual GIP/GLP-1 agonists (tirzepatide) at equivalent exposure.
Phase 3 TRIUMPH trial (results reported 2025–2026): A pivotal trial of nearly 900 participants, retatrutide produced 24.2–28.3% weight reduction depending on dose, compared to 2–6% for placebo. Additional benefits included:
The magnitude of weight loss reported in TRIUMPH is the largest yet achieved in a Phase 3 obesity trial for a non-surgical intervention.
One of retatrutide's most striking effects is the reduction in liver fat. Phase 2 trial results showed:
This mechanism—enhanced hepatic fat oxidation via glucagon receptor activation—is a primary driver of retatrutide's advantage over earlier compounds. For researchers studying metabolic liver disease, this is a major mechanistic discovery.
Current status (August 2026): Retatrutide is in Phase 3 development under the TRIUMPH program. FDA approval is anticipated in late 2026 or 2027, pending completion of ongoing cardiovascular safety and efficacy trials.
Eli Lilly is the developer; the compound is under investigation for obesity and metabolic disease. It is not yet approved for any indication and remains a research compound for preclinical and clinical study.
The conventional model of obesity focuses on appetite and caloric intake reduction—GLP-1's satiety effect. Retatrutide's superior outcomes suggest a more complex picture:
The combination of reduced intake plus enhanced expenditure produces a more robust weight loss than either component alone—consistent with the "energy balance" model of obesity.
Retatrutide's preclinical and clinical data have reshaped how researchers think about obesity pharmacology. The triple agonist model has spurred new investigations into each receptor's contribution and whether further optimization (adding amylin agonists, for instance) might achieve even greater effects.
For researchers, retatrutide serves as a natural comparison point for evaluating other metabolic peptides and small molecules—any new compound must be benchmarked against these Phase 3 outcomes.
Browse metabolic research peptides
Universe Peptide publishes research-focused education for the scientific community. Products are for laboratory research only. See more in our News & research updates.